Press and News Releases
ChromaCode making an impact
Press Releases
ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.
CARLSBAD, Calif., Aug. 10, 2023 /PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, today announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing
ChromaCode Announces Commercial Availability of HDPCR-based Non-Small-Cell Lung Cancer Assay
CARLSBAD, Calif. July 11, 2023 /PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, today announced an early-access commercial launch of a non-small-cell lung cancer assay based on innovative High Definition
ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East
CARLSBAD, Calif., April 27, 2023 – ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to
ChromaCode Showcases HDPCR Oncology Data on QuantStudio Absolute Q dPCR System at the AMP 2022 Annual Meeting
CARLSBAD, Calif. – November 1, 2022 – ChromaCode, Inc., which brings accessible and affordable insights to labs, patients and physicians through its innovative High Definition PCR (HDPCRTM) multiplexing solution, announced today that it will present its HDPCR oncology data, studied
ChromaCode’s Emergency Use Authorization (EUA) Expanded by FDA for High-Throughput HDPCR™ SARS-CoV-2 Real-Time PCR Assay
Over six million tests have been performed and analyzed using the HDPCR™ SARS-CoV-2 EUA assay and ChromaCode Cloud™ CARLSBAD, Calif. – February 23, 2022 – ChromaCode, Inc., a company redefining molecular testing through data science, announced today that the U.S. Food and
News Releases
ChromaCode starts early-access launch of lung cancer variant test
LabPulse: ChromaCode has begun an early-access commercial launch of a non-small cell lung cancer (NSCLC) assay that tests for variants in nine genes. The test is designed to address diagnostic problems that prevent patients from undergoing timely cancer biomarker testing
ChromaCode and Protean to launch assay for lung cancer in US
Medical Device Network: HDPCR is an advanced method for multiplexing biomarkers in a single, rapid assay across multiple sample types. ChromaCode has entered a strategic partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the
ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.
Street Insider: CARLSBAD, Calif., Aug. 10, 2023 /PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, today announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing
ChromaCode Initiates Strategic Shift to Oncology With New Leadership, Digital PCR Lung Cancer Test
GenomeWeb: NEW YORK – ChromaCode has begun to apply its qPCR multiplexing technology to digital PCR… View full article
New Products Posted to GenomeWeb: ChromaCode NSCLC Assay, Thermo Fisher Diomni Software, More
GenomeWeb: ChromaCode Non-Small-Cell Lung Cancer Assay… View full article
HDPCR Technology-Based Non-Small-Cell Lung Cancer Assay to Expand Options for Faster, Targeted Treatment
LabMedica: Non-small-cell lung cancer (NSCLC) represents the majority of lung cancer cases. Though targeted therapies have enhanced NSCLC survival rates recently, only around half of the patients receive timely biomarker testing for driver mutations to obtain targeted treatment. The barriers
ChromaCode Non-Small-Cell Lung Cancer Assay
360Dx: ChromaCode has launched a non-small-cell lung cancer (NSCLC) assay based on its High Definition PCR (HDPCR) technology for early-access customers. The assay panel detects actionable NSCLC variants in nine relevant genes using amplitude modulation and multi-spectral encoding. It requires low sample
ChromaCode commercially launches HDPCR-based NSCLC assay
Medical Device Network: The assay leverages amplitude modulation and multi-spectral encoding to identify actionable NSCLC variants in nine relevant genes. Genomics multiplexing platform company ChromaCode has commercially introduced the High Definition PCR (HDPCR)-based non-small-cell lung cancer (NSCLC) assay. Leveraging amplitude modulation
Six molecular diagnostics companies to watch
Labiotech: You may have heard of the enzyme-linked immunosorbent assay, more commonly known as the ELISA test, which is used to measure molecules like antibodies, antigens and proteins in biological samples. Used to diagnose infections caused by human immunodeficiency viruses
In Brief This Week: HTG Molecular, Prenetics, DiaSorin, DermTech, NanoString Technologies, More
GenomeWeb: NEW YORK – HTG Molecular said this week that in connection with its filing for Chapter 11… View full article
